Q4 2024 13F Holders as of 12/31/2024
-
Type / Class
-
Equity / Common Stock
-
Shares outstanding
-
80.7M
-
Number of holders
-
180
-
Total 13F shares, excl. options
-
40.5M
-
Shares change
-
+836K
-
Total reported value, excl. options
-
$292M
-
Value change
-
+$7.4M
-
Put/Call ratio
-
0.74
-
Number of buys
-
91
-
Number of sells
-
-65
-
Price
-
$7.21
Significant Holders of Altimmune, Inc. - Common Stock (ALT) as of Q4 2024
227 filings reported holding ALT - Altimmune, Inc. - Common Stock as of Q4 2024.
Altimmune, Inc. - Common Stock (ALT) has 180 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 40.5M shares
of 80.7M outstanding shares and own 50.12% of the company stock.
Largest 10 shareholders include BlackRock, Inc. (6.16M shares), AMERIPRISE FINANCIAL INC (5.25M shares), VANGUARD GROUP INC (4.43M shares), STATE STREET CORP (3.47M shares), TANG CAPITAL MANAGEMENT LLC (2.75M shares), GEODE CAPITAL MANAGEMENT, LLC (1.66M shares), Knoll Capital Management, LLC (1.12M shares), Bellevue Group AG (945K shares), MORGAN STANLEY (922K shares), and UBS Group AG (720K shares).
This table shows the top 180 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.